Type of information: Collaboration agreement
Compound: SARS-CoV-2 vaccine variants
Company: 20Med Therapeutics (NL) Wageningen University (NL) University of Twente (NL)
Therapeutic area: Infectious diseases
Type agreement: collaboration, research
Action mechanism: mRNA vaccine
* On June 1, 2021, 20Med Therapeutics announced that the company in collaboration with Wageningen University and University of Twente has started research into the development of SARS-CoV-2 vaccine variants based on 20Med’s ready-to-use polymer nanoparticle vaccine delivery platform.
In the first phase of the project, which has been successfully completed, the efficacy of the platform has been tested using the 20Med polymer nanoparticle technology in combination with the mRNA based on the first variant of the SARS-CoV-2 virus from Wuhan.
In the next phase new mRNA constructs will be designed and tested, based on the knowledge that is available about the different virus variants.
Financial terms: This research is funded by Oost NL via het Europees Fonds voor Regionale Ontwikkeling (EFRO).